6Tiroch K, Koch WM. p27 and p53 gene polymorphisms and restenosis following coronary implantation of drug-eluting stents. Cardiology,2009, 112:263-269.
7Browatzki M, aL Angiotensin Larsen D, Pfeiffer CA, et II stimulates matrix metalloproteinase secretion in human vascular smooth muscle cells via nuclear factor-kappaB and activator protein 1 in a redox-sensitive manner. J Vasc Res, 2005,42:415-423.
8Zhu DN, Wu BW, Fan XL. Physiology. SevenEdition. Beijing.. People~s Medical Publishing House ,2008:120-121.
9Jing T, Wang H, Srivenugopal KS,et al. Conditional expression of type 2 angiotensin II receptor in rat vascular smooth muscle cells reveals the interplay of the angiotensin system in matrix metalloproteinase 2 expression and vascular remodeling. Int J Mol Med, 2009,24:103-110.
10Huang Y,Salu K,Wang L,et al. Use of a tacrolimus- eluting stent to inhibit neointimal hyperplasia in a porcine coronary model. J Invasive Cardiol, 2005,17 : 142-148.
同被引文献30
1Meliga E, De Benedictis M, Gagnor A, et al. New drug-eluting stent implantation for recalcitrant in- stent restenosis treated with drug eluting stents, the Stent-in-Stent Cube ( SIS3 ) registry [J]. J Invasive Cardiol, 2011, 23:365-368.
2Davies A, Scott A. Acute coronary syndromes[J]. Starting to Read ECGs, 2014, 147-159.
3Van Tiel CM,Bonta PI, Rittersma SZ, et al. p27kipl- 838C > A single nucleotide polymorphism is associated with restenosis risk after coronary stenting and modulates p27kipl promoter activity[J]. Circulation, 2009, 120:669-676.
4Kang SJ, in-stent Mintz GS, Park DW, et al. Mechanisms of restenosis after drug-eluting inpalntation: intravascular ultrasound analysis Circ Cardiovasc Interv, 2011, 4:9-14.
5stent EJ]. Wilson WM1, Walsh S, Hanratty C, et al. A novel approach to the management of occlusive in-stent restenosis (ISR) . EuroIntervention, 2014, 20: 1285-1293.
6Ong PI, Athanasiadis A, vasomotor abnormalities Perne A, et al. Coronary in patients with stable angina after successful stent implantation but without in-stent restenosis[J]. Clin Res Cardiol, 2014, 103: 11-19.
7Harle T, Zeymer U, Sehwarz AK, et al. Use of drug-eluting stents in acute myocardial infarction with persistent ST-segment elevation: results of the ALKK PCI-registry. Clin Res Cardiol, 2014, 103: 373 -380.
8Richardt G, Leschke M, Abdel-Wahab M, et al. Clinical outcomes of the resolute zotarolimus-eluting stent in patients with in-stent restenosis.. 2-year results from a pooled analysis[J]. JACC Cardiovasc Interv, 2013, 6:905 -913.
9Kigawa T, Matsumaru Y, Hayakawa M, et al. Cilostazol reduces restenosis after carotid artery stenting[J]. J Vasc Surg, 2010,51 : 51-56.
10Saito T, Hokimoto S, Oshima S,et al. Metal allergic reation in chronic refractory in stent restenosis [J]. Cardiovasc Revasc Med, 2009,10:174- 182.
